<p>Kepler Capital 分析师 David Evans 于 5 月 8 日维持了对诺华制药的买入评级，并设定了 135.00 瑞士法郎的目标价。该公司股票上周五收于 113.36 瑞士法郎。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
<p>根据 TipRanks，Evans 在 12193 名分析师中排名第 7060。</p>
<p>除了 Kepler Capital，诺华制药还在 5 月 7 日获得了美国银行证券的 Sachin Jain 的买入评级。然而，在 5 月 8 日，瑞银维持了对诺华制药的持有评级（六瑞士：NOVN）。</p>

诺华制药

纽交所高增长板生物技术指数 ETF - First Trust

<p>Kepler Capital 分析师 David Evans 于 5 月 8 日对诺华制药 (NOVN) 维持了买入评级，目标价为 135.00 瑞士法郎。该股票上周五收于 113.36 瑞士法郎。此外，美国银行证券也对诺华制药发布了买入评级，而瑞银在同一天维持了持有评级</p>

<p>Kepler Capital analyst David Evans maintained a Buy rating on Novartis AG on May 8 and set a price target of CHF135.00. The company’s shares closed last Friday at CHF113.36.</p>
<div class="lb-trans"><p>Kepler Capital 分析师 David Evans 于 5 月 8 日维持了对诺华制药的买入评级，并设定了 135.00 瑞士法郎的目标价。该公司股票上周五收于 113.36 瑞士法郎。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，以便做出更聪明、更精准的决策</li>
<li>发现表现优异的股票投资理念，并升级到市场领先者的投资组合，使用智能投资者精选</li>
</ul>
</div><p>According to TipRanks, Evans is ranked #7060 out of 12193 analysts.</p>
<div class="lb-trans"><p>根据 TipRanks，Evans 在 12193 名分析师中排名第 7060。</p>
</div><p>In addition to Kepler Capital , Novartis AG also received a Buy from Bank of America Securities’s Sachin Jain in a report issued on May 7. However, on May 8, UBS maintained a Hold rating on Novartis AG (Six Swiss: NOVN).</p>
<div class="lb-trans"><p>除了 Kepler Capital，诺华制药还在 5 月 7 日获得了美国银行证券的 Sachin Jain 的买入评级。然而，在 5 月 8 日，瑞银维持了对诺华制药的持有评级（六瑞士：NOVN）。</p>
</div>

Kepler Capital  Remains a Buy on Novartis AG (NOVN)

Tip Ranks

Novartis AG

美国制药 ETF - iShares

医疗业 ETF - Vanguard

医药突破 ETF - ALPS

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 3 倍做多 - Direxion

标普全球医疗股指数 ETF - iShares

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

动态生物技术与基因组 ETF - Invesco

美国银行

瑞银集团

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

开普勒资本继续对诺华制药（NOVN）维持买入评级